166 related articles for article (PubMed ID: 16178436)
1. [Vasoactive polypeptides and cardiovascular endocrine diseases].
Zeng ZP
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Aug; 27(4):443-5. PubMed ID: 16178436
[TBL] [Abstract][Full Text] [Related]
2. The emerging role of apelin in cardiovascular disease and health.
Quazi R; Palaniswamy C; Frishman WH
Cardiol Rev; 2009; 17(6):283-6. PubMed ID: 19829178
[TBL] [Abstract][Full Text] [Related]
3. [Advances in cardiovascular system endocrine].
Tang CS; Qi YF
Sheng Li Ke Xue Jin Zhan; 2007 Jan; 38(1):19-24. PubMed ID: 17438948
[TBL] [Abstract][Full Text] [Related]
4. [Peptidergic mechanisms in the regulation of emotional and motivational behavior].
Krupina NA; Khlebnikova NN
Usp Fiziol Nauk; 2010; 41(2):3-26. PubMed ID: 20469601
[TBL] [Abstract][Full Text] [Related]
5. Growth hormone and growth factors in endocrinology and metabolism. Foreword.
Horm Res; 2007; 68 Suppl 5():1. PubMed ID: 18297763
[No Abstract] [Full Text] [Related]
6. [Endogenous digitalis-like substance. II. Relation to pathologic states and diseases].
Martinka E
Vnitr Lek; 1995 Oct; 41(10):719-23. PubMed ID: 8578707
[TBL] [Abstract][Full Text] [Related]
7. [Vascular permeability in glaucoma patients suffering from cardiovascular and endocrine diseases].
Denisiuk NB
Vrach Delo; 1979 Jun; (6):30-3. PubMed ID: 473716
[No Abstract] [Full Text] [Related]
8. White adipose tissue and cardiovascular disease.
Matsuzawa Y
Best Pract Res Clin Endocrinol Metab; 2005 Dec; 19(4):637-47. PubMed ID: 16311222
[TBL] [Abstract][Full Text] [Related]
9. [Diseases of the 3d age].
Harlay A
Infirm Fr; 1979 Feb; (202):19-25. PubMed ID: 253682
[No Abstract] [Full Text] [Related]
10. Vasoactive peptides in cardiovascular (patho)physiology.
Callera G; Tostes R; Savoia C; Muscara MN; Touyz RM
Expert Rev Cardiovasc Ther; 2007 May; 5(3):531-52. PubMed ID: 17489676
[TBL] [Abstract][Full Text] [Related]
11. [Emphasize the role of bioactive small molecules in the homeostasis regulation of cardiovascular system].
Tang CS; Pu D
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Aug; 27(4):440-2. PubMed ID: 16178435
[TBL] [Abstract][Full Text] [Related]
12. Pathology, pathophysiology, and treatment strategies of endocrine disorders and their cardiac complications.
Luk A; Ezzat S; Butany J
Semin Diagn Pathol; 2013 Aug; 30(3):245-62. PubMed ID: 24144293
[TBL] [Abstract][Full Text] [Related]
13. 'Relaxin' the stiffened heart and arteries: the therapeutic potential for relaxin in the treatment of cardiovascular disease.
Samuel CS; Du XJ; Bathgate RA; Summers RJ
Pharmacol Ther; 2006 Nov; 112(2):529-52. PubMed ID: 16814863
[TBL] [Abstract][Full Text] [Related]
14. [Coenzyme Q--clinical significance].
Jacheć W; Wodniecki J; Kamiński K
Wiad Lek; 1994; 47(21-24):850-3. PubMed ID: 8999700
[TBL] [Abstract][Full Text] [Related]
15. Endocrine disorders affecting the cardiovascular system.
Coffland FI
Crit Care Nurs Clin North Am; 1994 Dec; 6(4):735-45. PubMed ID: 7766350
[TBL] [Abstract][Full Text] [Related]
16. Small but powerful: short peptide hormones and their role in autoimmune inflammation.
Lühder F; Lee DH; Gold R; Stegbauer J; Linker RA
J Neuroimmunol; 2009 Dec; 217(1-2):1-7. PubMed ID: 19748684
[TBL] [Abstract][Full Text] [Related]
17. Developments in ghrelin biology and potential clinical relevance.
Smith RG; Jiang H; Sun Y
Trends Endocrinol Metab; 2005 Nov; 16(9):436-42. PubMed ID: 16213742
[TBL] [Abstract][Full Text] [Related]
18. [Investigation of the absorptive-secrery function of the liver].
Leshchinskiĭ LA; Trusov VV; Belosludtsev IA
Sov Med; 1969 Nov; 32(11):16-20. PubMed ID: 5382889
[No Abstract] [Full Text] [Related]
19. Toward revealing the roles for intermedin in the community of vasoactive peptides.
Evans JJ
Hypertens Res; 2009 Oct; 32(10):824-5. PubMed ID: 19680257
[No Abstract] [Full Text] [Related]
20. Ghrelin: a new hormone with endocrine and non-endocrine activities.
Baldelli R; Bellone S; Broglio F; Ghigo E; Bona G
Pediatr Endocrinol Rev; 2004 Sep; 2(1):8-14. PubMed ID: 16429099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
